Skip to main content

Advertisement

Table 2 Lesion volumes at Weeks 24 and 48 compared to baseline

From: Effect of peginterferon beta-1a on MRI measures and achieving no evidence of disease activity: results from a randomized controlled trial in relapsing-remitting multiple sclerosis

Characteristic Placebo (n = 476) Peginterferon beta-1a 125 μg every 4 weeks Peginterferon beta-1a 125 μg every 2 weeks
(n = 462) (n = 457)
Mean change from baseline in T2 lesion volume, cm3, at 24 weeks 0.34 0.14 −0.22
P value vs. placebo   p = 0.0006 p < 0.0001
P value vs. every 4 weeks - - p < 0.0001
Mean change from baseline in T2 lesion volume, cm3, at 48 weeks 0.77 0.06 −0.26
P value vs. placebo   p < 0.0001 p < 0.0001
P value vs. every 4 weeks - - p < 0.0001
Mean change from baseline in TI hypointense lesion volume, cm3, at 24 weeks 0.29 0.31 0.18
P value vs. placebo   p = 0.22 p = 0.0002
P value vs. every 4 weeks - - p = 0.014
Mean change from baseline in TI hypointense lesion volume, cm3, at 48 weeks 0.54 0.57 0.32
P value vs. placebo   p = 0.18 p < 0.0001
P value vs. every 4 weeks - - p = 0.0032